• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    12/30/25 4:15:01 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care
    Get the next $WOK alert in real time by email
    6-K 1 ea0271304-6k_workmed.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-42256

     

    WORK Medical Technology Group LTD

     

    Floor 23, No. 2 Tonghuinan Road

    Xiaoshan District, Hangzhou City, Zhejiang Province

    People’s Republic of China, 241003

    (Address of principal executive offices) 

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Consolidation of Ordinary Shares

     

    On October 21, 2025, WORK Medical Technology Group LTD (the “Company”) held an extraordinary general meeting of shareholders (the “EGM”). During the EGM, the shareholders passed certain resolutions with respect to: (i) one or more share consolidations of all of the authorized, issued, and outstanding shares of the Company (collectively, the “Shares”), each at such consolidation ratio and with such effective time as the board of directors of the Company (the “Board”) may determine in its sole discretion (together, the “Share Consolidations,” and each, a “Share Consolidation”); provided, however, that the accumulated consolidation ratio for any and all such Share Consolidations shall be no less than 2:1 nor greater than 250:1, with such consolidated Shares having the same rights and being subject to the same restrictions (save as to nominal value) as the existing Shares of each class as set out in the Company’s existing amended and restated memorandum and articles of association; and (ii) the adoption of a further amended and restated memorandum of association to reflect the relevant Share Consolidation.

     

    On November 29, 2025, the Board passed certain resolutions with respect to (i) a consolidation of the Shares at the ratio of 100:1; and (ii) the adoption of an amended and restated memorandum of association in substitution for, and to the entire exclusion of, the Company’s existing memorandum of association, to reflect the Share Consolidation.

     

    Reason for the Share Consolidation. The Share Consolidation was implemented so that the Company can expeditiously meet the continued listing standard of the Nasdaq Stock Market (“Nasdaq”) relating to the minimum bid price under Nasdaq Listing Rule 5550(a)(2), and to mitigate the risk of the Company being delisted from the Nasdaq.

     

    Effective Date; Symbol; CUSIP Number. The effective date of the Share Consolidation was December 29, 2025 (the “Effective Date”), which was reflected on the Nasdaq marketplace at the opening of business on December 29, 2025, whereupon the Company’s Class A ordinary shares began trading on a post-consolidation basis. The Company’s Class A ordinary shares continue to trade on Nasdaq under the same symbol “WOK” with a new CUSIP Number, G9767H125.

     

    Adjustment; No Fractional Shares. On the Effective Date, the number of the Company’s ordinary shares held by each shareholder was converted into the number of ordinary shares held by such shareholder immediately prior to the Share Consolidation divided by one hundred (100), with any resulting fractional shares rounded up to the whole number of shares. 

     

    Non-Certificated Shares. Shareholders who hold their ordinary shares in electronic form at brokerage firms did not have to take any action, as the Share Consolidation was automatically reflected in their brokerage accounts.

     

    Authorized Shares. On the Effective Date, the Company’s authorized ordinary shares were consolidated at the ratio of one hundred-for-one, and the authorized share capital of the Company became US$100,000,000 divided into 16,000,000 Class A ordinary shares of par value US$5.00 each and 4,000,000 Class B ordinary shares of par value US$5.00 each.

     

    Capitalization. As of December 28, 2025, the Company had 122,001,406 ordinary shares issued and outstanding, composed of 121,925,481 Class A ordinary shares and 75,925 Class B ordinary shares. As a result of the Share Consolidation, as of the Effective Date, there were approximately 1,220,015 ordinary shares issued and outstanding, composed of approximately 1,219,255 Class A ordinary shares and 760 Class B ordinary shares (subject to the adjustment of rounding fractional shares into additional whole shares).

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: December 30, 2025

     

      WORK Medical Technology Group LTD
         
      By: /s/ Shuang Wu
      Name:  Shuang Wu
      Title: Chief Executive Officer

     

    2

     

    Get the next $WOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Medical Treatment Technology Co., Ltd. ("Hunan Saitumofei") has entered into a one-year exclusive distribution agreement (the "Agreement") with Shanghai Benke Medical Technology Co., Ltd. ("Shanghai Benke") to promote and distribute its newly launched AI-Automated Blood Cell Morphology Analyzer (CM-B600) (the "Analyzer") in East China throughout 2026. Th

    12/29/25 9:35:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer

    Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's

    12/29/25 9:00:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

    Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (NASDAQ:WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the "Reverse Stock Split"). The Company's Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company's Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "WOK," with a new CUSIP number G9767H125. The Reverse

    12/24/25 11:30:00 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    $WOK
    SEC Filings

    View All

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    2/9/26 9:55:09 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by WORK Medical Technology Group LTD

    20-F - WORK Medical Technology Group LTD (0001929783) (Filer)

    1/30/26 5:07:52 PM ET
    $WOK
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by WORK Medical Technology Group LTD

    6-K - WORK Medical Technology Group LTD (0001929783) (Filer)

    1/5/26 8:00:35 AM ET
    $WOK
    Medical/Dental Instruments
    Health Care